Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008302 | 0.95 | MAPT (0.68) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008165 | 0.95 | MAPT (0.68) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008294 | 0.95 | MAPT (0.67) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13694824 | 0.92 | MAPT (0.60) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008328 | 0.90 | MAPT (0.59) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008295 | 0.90 | MAPT (0.70) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008298 | 0.90 | ALDH1A1 (0.65) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008166 | 0.89 | ALDH1A1 (0.67) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008293 | 0.87 | ALDH1A1 (0.66) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12008151 | 0.87 | MAPT (0.63) | MAPTTP53SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MAPT 1929/4885TP53 73/4885SMN1; SMN2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.